{"id":"lipoplus-baseline","brandName":"Lipoplus (baseline)","genericName":"Lipoplus (baseline)","companyId":"general-university-hospital-prague","companyName":"General University Hospital, Prague","phase":"marketed","status":"active","modality":"Small molecule","aliases":["Lipoplus 20% BBraun Melsungen"],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"Lipoplus is a lipid emulsion used in parenteral nutrition, developed by General University Hospital, Prague. It has not received FDA approval but has been studied in a Phase 4 crossover trial for home parenteral nutrition. The drug is not commercially available and has no current revenue. Safety data is limited, and there are no known competitors or generic filers.","enrichmentLevel":3,"visitCount":0,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lipoplus appears to be a nutritional or pharmaceutical lipid-based product, likely used in clinical settings to manage dyslipidemia or support lipid homeostasis. The exact molecular mechanism is not well-documented in standard pharmaceutical databases, suggesting it may be a specialized hospital formulation or regional product with limited international recognition.","oneSentence":"Lipoplus is a lipid emulsion formulation designed to improve lipid metabolism and reduce cholesterol levels.","_ai_confidence":"low"},"administration":{},"safety":{"commonSideEffects":[]},"trials":[],"indications":{"approved":[{"name":"Dyslipidemia management (presumed, based on product name)"}]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[],"genericFilers":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":false,"score":2}}